Hamzah Aideed, M.Sc.
Principal Analyst, Biosimilars
Clarivate
In recent years, the availability of biosimilars has significantly disrupted the biopharmaceutical industry, and there are many more on the way with over 400 biosimilars in clinical development globally. As regions around the world continue to pave regulatory frameworks for biosimilar development, alongside expiring patents for key biologic drugs, this evolving landscape presents a commercial opportunity to biosimilar manufacturers that is undeniably large.
In this webinar, we look at the biosimilar landscape across the major markets—where biosimilars have become well-established—providing an overview of regulatory guidelines, clinical development activity, and drivers and barriers to biosimilar adoption